MIRA Pharmaceuticals' Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies
Portfolio Pulse from Vandana Singh
MIRA Pharmaceuticals' stock surged after announcing successful preclinical results for its oral ketamine analog, Ketamir-2, which achieved complete normalization of neuropathic pain in animal studies. The company is optimistic about future human trials.
August 26, 2024 | 1:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals' stock rose significantly after announcing that its oral ketamine analog, Ketamir-2, achieved complete normalization of neuropathic pain in animal studies. This positions Ketamir-2 as a potential breakthrough treatment for neuropathic pain.
The announcement of Ketamir-2's successful preclinical results led to a significant increase in MIRA's stock price, indicating strong investor confidence in the potential of this new treatment. The stock's trading volume also doubled, reflecting heightened market interest.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100